X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
CF101 (piclidenoson), a novel, first-in-class, A3 adenosine receptor agonist (A3AR) small molecule, orally bioavailable drug. It is under phase 3 clinical development for the treatment of children suffering from psoriasis.
Lead Product(s): Piclidenoson
Therapeutic Area: Dermatology Product Name: CF101
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 18, 2023
Details:
The company intends to use the net proceeds for funding research and development and clinical trials for its pipeline, including CF101 (piclidenoson), an agonist to the A3 adenosine receptor, currently in a Phase III clinical study for the treatment of psoriasis.
Lead Product(s): Piclidenoson
Therapeutic Area: Dermatology Product Name: CF101
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: H.C. Wainwright & Co.
Deal Size: $3.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering November 21, 2023
Details:
The agreement aims for the development of CF101 (piclidenoson), a novel, first-in-class, A3 adenosine receptor agonist (A3AR) small molecule, orally bioavailable drug, for the treatment of Lowe Syndrome, a high medical need with no drug available.
Lead Product(s): Piclidenoson
Therapeutic Area: Genetic Disease Product Name: CF101
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Fondazione Telethon
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement August 24, 2023
Details:
CF101 (piclidenoson) is a novel, first-in-class, A3 adenosine receptor agonist small molecule, orally bioavailable drug. The drug inhibits inflammatory cytokines IL-17 and IL-23 and the induction of apoptosis of patients’ skin cell keratinocytes like psoriasis.
Lead Product(s): Piclidenoson
Therapeutic Area: Dermatology Product Name: CF101
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 18, 2023
Details:
CF101 (piclidenoson) is a novel, first-in-class, A3 adenosine receptor agonist (A3AR) small molecule, orally bioavailable drug. The drug inhibits inflammatory cytokines IL-17 and IL-23 and the induction of apoptosis of patients’ skin cell keratinocytes.
Lead Product(s): Piclidenoson
Therapeutic Area: Dermatology Product Name: CF101
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 29, 2023
Details:
CF101 (piclidenoson) is a novel, first-in-class, A3 adenosine receptor agonist (A3AR) small molecule, orally bioavailable drug. The drug inhibits inflammatory cytokines IL-17 and IL-23 and the induction of apoptosis of patients’ skin cell keratinocytes.
Lead Product(s): Piclidenoson
Therapeutic Area: Dermatology Product Name: CF101
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 10, 2023
Details:
Can-Fite intends to use the net proceeds for funding research and development and clinical trials. The company’s lead drug candidate, CF101 (piclidenoson) recently reported topline results in a Phase III trial for psoriasis.
Lead Product(s): Piclidenoson
Therapeutic Area: Dermatology Product Name: CF101
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: H.C. Wainwright & Co.
Deal Size: $7.5 million Upfront Cash: Undisclosed
Deal Type: Public Offering January 11, 2023
Details:
CF101 (piclidenoson) is a novel, first-in-class, A3 adenosine receptor agonist (A3AR) small molecule, orally bioavailable drug. The drug inhibits inflammatory cytokines IL-17 and IL-23 and the induction of apoptosis of patients’ skin cell keratinocytes.
Lead Product(s): Piclidenoson
Therapeutic Area: Dermatology Product Name: CF101
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 10, 2023
Details:
CF101 (piclidenoson) is novel, first-in-class, A3 adenosine receptor agonist (A3AR) small molecule, orally bioavailable drug with an excellent safety profile demonstrating evidence of efficacy in Phase II clinical studies.
Lead Product(s): Piclidenoson
Therapeutic Area: Dermatology Product Name: CF101
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 12, 2022
Details:
CF101 (piclidenoson) is a novel, first-in-class, A3 adenosine receptor agonist (A3AR) small molecule, orally bioavailable drug with an excellent safety profile demonstrating evidence of efficacy in Phase II clinical studies.
Lead Product(s): Piclidenoson
Therapeutic Area: Dermatology Product Name: CF101
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 22, 2022
Details:
CF101 (piclidenoson) is a novel, first-in-class, A3 adenosine receptor agonist (A3AR) small molecule, orally bioavailable drug with an excellent safety profile demonstrating evidence of efficacy in Phase II clinical studies.
Lead Product(s): Piclidenoson
Therapeutic Area: Dermatology Product Name: CF101
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 11, 2022
Details:
Data suggest Piclidenoson (CF101) and Namodenoson could potentially be the first A3AR agonists to achieve FDA approval and provide clinicians with new oral and safe drugs in the arsenal for fighting psoriasis, liver cancer, and NASH.
Lead Product(s): Piclidenoson
Therapeutic Area: Dermatology Product Name: CF101
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 09, 2022
Details:
CF101 (piclidenoson), is an oral drug that is currently in a Phase III clinical study for the treatment of psoriasis. All human clinical studies have demonstrated this drug to have an excellent safety profile.
Lead Product(s): Piclidenoson
Therapeutic Area: Dermatology Product Name: CF101
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 28, 2022
Details:
CF101 (piclidenoson), an A3 adenosine receptor agonist involving inhibition of 2 cytokines, interleukin-17 and interleukin-23, are both pivotal for the formation of skin lesions. Piclidenoson has also recently been shown to induce death of pathological skin cells.
Lead Product(s): Piclidenoson
Therapeutic Area: Dermatology Product Name: CF101
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 08, 2022
Details:
Piclidenoson is a novel, first-in-class, A3 adenosine receptor agonist (A3AR) small molecule, orally bioavailable drug with a favorable therapeutic index demonstrated in Phase II clinical studies.
Lead Product(s): Piclidenoson
Therapeutic Area: Dermatology Product Name: CF101
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 07, 2021
Details:
Piclidenoson is a novel, first-in-class, A3 adenosine receptor agonist (A3AR) small molecule, orally bioavailable drug with a favorable therapeutic index demonstrated in Phase II clinical studies.
Lead Product(s): Piclidenoson
Therapeutic Area: Dermatology Product Name: CF101
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 02, 2021
Details:
75% of patients have been enrolled in Can-Fite’s Phase III Comfort™ study designed to establish Piclidenoson’s superiority compared to placebo and non-inferiority compared to Apremilast (Otezla®) in patients with moderate to severe plaque psoriasis.
Lead Product(s): Piclidenoson
Therapeutic Area: Dermatology Product Name: CF101
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 29, 2021
Details:
The randomized, double blind study is evaluating the benefits of treatment of Piclidenoson plus standard supportive care vs. placebo plus SSC in patients hospitalized with moderate to severe COVID-19, as defined by the U.S. NIH COVID-19 Treatment Guidelines.
Lead Product(s): Piclidenoson
Therapeutic Area: Infections and Infectious Diseases Product Name: CF101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 22, 2021
Details:
Piclidenoson is now being evaluated in the COMFORT Phase III clinical study. The COMFORT study is designed to establish Piclidenoson’s superiority as compared to placebo and non-inferiority compared to Otezla® in patients with moderate-to-severe plaque psoriasis.
Lead Product(s): Piclidenoson
Therapeutic Area: Dermatology Product Name: CF101
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 20, 2021
Details:
The Company's lead drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis and a Phase II study in the treatment of moderate COVID-19. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma.
Lead Product(s): Piclidenoson
Therapeutic Area: Dermatology Product Name: CF101
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $130.0 million Upfront Cash: Undisclosed
Deal Type: Agreement March 30, 2021
Details:
Ewopharma will have the exclusive right to market and sell Piclidenoson in Central Eastern European (CEE) countries and Namodenoson in CEE countries and Switzerland.
Lead Product(s): Piclidenoson
Therapeutic Area: Dermatology Product Name: CF101
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Ewopharma
Deal Size: $42.7 million Upfront Cash: $2.2 million
Deal Type: Licensing Agreement March 16, 2021
Details:
Independent Data Monitoring Committee (IDMC) conducted a pre-planned interim analysis of the Company’s Phase III Comfort™ trial of Piclidenoson for the treatment of psoriasis and recommended to continue with this psoriasis study.
Lead Product(s): Piclidenoson
Therapeutic Area: Dermatology Product Name: CF101
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 06, 2020
Details:
FDA has issued a “safe to proceed” notice for Can-Fite’s Investigational New Drug (IND) application for a Phase II study of its lead drug candidate Piclidenoson in the treatment of COVID-19.
Lead Product(s): Piclidenoson
Therapeutic Area: Infections and Infectious Diseases Product Name: CF101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 31, 2020
Details:
Can-Fite BioPharma has submitted an Investigational New Drug application to U.S. FDA for a Phase II study of its lead drug candidate Piclidenoson in the treatment of COVID-19. The IND application is based on feedback and guidance from the FDA from prior pre-IND advice.
Lead Product(s): Piclidenoson
Therapeutic Area: Infections and Infectious Diseases Product Name: CF101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 27, 2020
Details:
The Phase II study titled, “Piclidenoson for Treatment of COVID-19 – A Randomized, Double Blind, Placebo-Controlled Trial” is a pilot trial in a population of hospitalized patients who all receive standard supportive care.
Lead Product(s): Piclidenoson
Therapeutic Area: Infections and Infectious Diseases Product Name: CF101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 15, 2020
Details:
The planned Phase II trial will evaluate the efficacy and safety of Piclidenoson, when added to the current standard of care treatment, for COVID-19 infected patients with moderate-to-severe symptoms.
Lead Product(s): Piclidenoson
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 09, 2020
Details:
Piclidenoson’s anti-viral, anti-inflammatory, anti-rheumatic properties and excellent safety profile make it a strong candidate for the potential treatment of COVID-19.
Lead Product(s): Piclidenoson
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 15, 2020
Details:
Study will treat 40 COVID-19 infected patients with Piclidenoson, who are hospitalized with moderate-to-severe symptoms.
Lead Product(s): Piclidenoson
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 13, 2020
Details:
Interim analysis of the Phase III Comfort trial designed to evaluate the Company’s drug candidate, Piclidenoson, in the treatment of moderate-to-severe plaque psoriasis.
Lead Product(s): Piclidenoson
Therapeutic Area: Dermatology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 30, 2020
Details:
The agreement will support research directed by Dr. Kamel Khalili, aimed to explore anti-viral activity of Piclidenoson on Coronaviruses viral load in a mammalian cell model system as a first step.
Lead Product(s): Piclidenoson
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Can-Fite BioPharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 13, 2020
Details:
Can Fite is exploring the possibility to collaborate with leading virology labs to explore the anti-viral effect of its drugs against the Coronavirus based on the known anti-viral effects.
Lead Product(s): Piclidenoson
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 05, 2020
Details:
This year, Can-Fite's reports expand the growing data body demonstrating that both Piclidenoson and Namodenoson have beneficial safety profiles and risk-benefit ratios in over 1,500 patients.
Lead Product(s): Piclidenoson
Therapeutic Area: Dermatology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 03, 2020
Details:
The Phase III ACRobat™ RA study is designed to establish Piclidenoson’s superiority compared to placebo and non-inferiority compared to methotrexate in patients with RA.
Lead Product(s): Piclidenoson
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 03, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
